Quince Therapeutics (QNCX) Projected to Post Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX) is expected to post its quarterly earnings results on Monday, March 24th. Analysts expect Quince Therapeutics to post earnings of ($0.18) per share for the quarter.

Quince Therapeutics Stock Performance

QNCX stock opened at $1.38 on Friday. The firm has a market cap of $60.72 million, a PE ratio of -1.11 and a beta of 0.71. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The business has a 50 day moving average of $1.50 and a 200-day moving average of $1.42. Quince Therapeutics has a 12-month low of $0.51 and a 12-month high of $2.45.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. D. Boral Capital reaffirmed a “buy” rating and issued a $12.00 target price on shares of Quince Therapeutics in a report on Wednesday, February 5th. Brookline Capital Management started coverage on Quince Therapeutics in a report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price objective for the company. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $9.50.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.